{
    "clinical_study": {
        "@rank": "51805", 
        "arm_group": [
            {
                "arm_group_label": "Desflurane", 
                "arm_group_type": "Active Comparator", 
                "description": "Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase"
            }, 
            {
                "arm_group_label": "Xenon", 
                "arm_group_type": "Experimental", 
                "description": "Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a monocentric study in 2 steps. First, there is a safety part to assess the\n      feasibility of using Xenon in association with a thoracic epidural analgesia.\n\n      A maximum of 9 patients will be enrolled in this first step. If the association is\n      considered as safe, the second step will be initiated. This part will be randomized, simple\n      blinded with 2 arms. 28 patients will be enrolled and will be followed during 45 days."
        }, 
        "brief_title": "A Study Which Compares the Efficacy of Xenon and Desflurane in Association With a Thoracic Epidural Analgesia", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The first step is divided into 3 parts. 9 patients will be sequentially enrolled (3 patients\n      in each part).\n\n      The patients will be followed during 45 days and the following rules will be used to assess\n      the safety:\n\n      First  part: if no toxicity: initiation of step 2. If 1/3 toxicity : start of the second\n      part. If 2 or 3/3 toxicity : end of the study Second part: same rules and possible start of\n      the third part. Third part: if no toxicity: initiation of step 2. If 1 or more toxicity :\n      end of the study.\n\n      The safety will be assessed after each part by an independent data safety monitoring board."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Older than 18 years old\n\n          -  Planned surgery for oncologic colic and/or rectal surgery\n\n          -  ASA score I or II\n\n          -  Indication of complementary thoracic epidural analgesia\n\n          -  Agree to use an effective form of contraception\n\n          -  Patients who can understand, read and write French language\n\n          -  Covered by a medical insurance\n\n          -  Patients who have dated/signed an inform consent\n\n        Exclusion Criteria:\n\n          -  Unstable angina within the 30 last days\n\n          -  Myocardial infarction within 28 days prior to surgery\n\n          -  Uncontrolled arterial high blood pressure\n\n          -  Severe cardiac insufficiency\n\n          -  Severe chronic obstructive pneumopathy\n\n          -  Patient who requires FiO2 > 40%\n\n          -  Patient already enrolled in a clinical study which may interfere with the present\n             study\n\n          -  Known hypersensitivity to one of the study drugs\n\n          -  History or familial history of malignant hyperthermia\n\n          -  Documented high intracranial pressure\n\n          -  Eclampsia or pre-eclampsia\n\n          -  Pregnant or breastfeeding woman\n\n          -  Liver injury (icterus) and/or unexplained fever and/or eosinophilia after halogen\n             exposure\n\n          -  Failure in epidural anesthesia installation\n\n          -  Patient refusal\n\n          -  Patient who can't be compliant to the present protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696630", 
            "org_study_id": "XENON", 
            "secondary_id": [
                "2012-002155-41", 
                "ET2012-19"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Xenon", 
                "intervention_name": "Xenon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Desflurane", 
                "intervention_name": "Desflurane", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Xenon", 
                "Desflurane"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "maintenance of anesthesia", 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "LYON Cedex 08", 
                    "country": "France", 
                    "zip": "69373"
                }, 
                "name": "Centre L\u00e9on B\u00e9rard"
            }, 
            "investigator": [
                {
                    "last_name": "Georges ROMERO, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Edouard AUBERT, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Patrick BACHMANN, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Henri-Jacques CLEMENT, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anne-Laure DAUNIZEAU-WALKER, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Baptiste VALLEIX, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jean-Edgard MAZERES, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fabienne MONTANGE, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "V\u00e9ronique PERES-BACHELOT, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "St\u00e9phanie POUDEROUX-MARTIN, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Herv\u00e9 ROSAY, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Henri SEBBAN, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study, Randomized, Monocentric, Single-blind, Comparing the Efficacy of Gases Xenon and Desflurane , in Association With a Thoracic Epidural Analgesia in Maintenance Phase of a Colorectal Oncologic Surgery", 
        "overall_contact": {
            "email": "julien.gautier@lyon.unicancer.fr", 
            "last_name": "Julien GAUTIER", 
            "phone": "+33 4 26 55 68 29"
        }, 
        "overall_contact_backup": {
            "email": "valerie.fouillat@lyon.unicancer.fr", 
            "last_name": "Val\u00e9rie FOUILLAT", 
            "phone": "+33 4 78 78 79 39"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The initial value (taken just before anesthesia induction) will be compared to the lowest value of mean Arterial Pressure observed during the whole maintenance phase.", 
            "measure": "Assess the fluctuation of peroperative mean Arterial Pressure", 
            "safety_issue": "No", 
            "time_frame": "during the whole maintenance phase, an expected average of 6 hours"
        }, 
        "reference": [
            {
                "PMID": "11379681", 
                "citation": "Nakata Y, Goto T, Ishiguro Y, Terui K, Kawakami H, Santo M, Niimi Y, Morita S. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. Anesthesiology. 2001 Apr;94(4):611-4."
            }, 
            {
                "PMID": "16782975", 
                "citation": "Rasmussen LS, Schmehl W, Jakobsson J. Comparison of xenon with propofol for supplementary general anaesthesia for knee replacement: a randomized study. Br J Anaesth. 2006 Aug;97(2):154-9. Epub 2006 Jun 17."
            }, 
            {
                "PMID": "18165567", 
                "citation": "Salmi E, Laitio RM, Aalto S, Maksimow AT, L\u00e5ngsj\u00f6 JW, Kaisti KK, Aantaa R, Oikonen V, Mets\u00e4honkala L, N\u00e5gren K, Korpi ER, Scheinin H. Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg. 2008 Jan;106(1):129-34, table of contents."
            }, 
            {
                "PMID": "14834873", 
                "citation": "CULLEN SC, GROSS EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951 May 18;113(2942):580-2."
            }, 
            {
                "PMID": "17325504", 
                "citation": "Wappler F, Rossaint R, Baumert J, Scholz J, Tonner PH, van Aken H, Berendes E, Klein J, Gommers D, Hammerle A, Franke A, Hofmann T, Schulte Esch J; Xenon Multicenter Study Research Group. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology. 2007 Mar;106(3):463-71."
            }, 
            {
                "PMID": "17468494", 
                "citation": "Baumert JH, Hein M, Hecker KE, Satlow S, Schnoor J, Rossaint R. Autonomic cardiac control with xenon anaesthesia in patients at cardiovascular risk. Br J Anaesth. 2007 Jun;98(6):722-7. Epub 2007 Apr 27."
            }, 
            {
                "PMID": "7909641", 
                "citation": "Luttropp HH, Thomasson R, Dahm S, Persson J, Werner O. Clinical experience with minimal flow xenon anesthesia. Acta Anaesthesiol Scand. 1994 Feb;38(2):121-5."
            }, 
            {
                "PMID": "12502972", 
                "citation": "Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle AF, Nagele P; Xenon Study Group. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology. 2003 Jan;98(1):6-13."
            }, 
            {
                "PMID": "10434815", 
                "citation": "Dupont J, Tavernier B, Ghosez Y, Durinck L, Thevenot A, Moktadir-Chalons N, Ruyffelaere-Moises L, Declerck N, Scherpereel P. Recovery after anaesthesia for pulmonary surgery: desflurane, sevoflurane and isoflurane. Br J Anaesth. 1999 Mar;82(3):355-9."
            }, 
            {
                "PMID": "20459661", 
                "citation": "Stuttmann R, Jakubetz J, Schultz K, Sch\u00e4fer C, Langer S, Ullmann U, Hilbert P. Recovery index, attentiveness and state of memory after xenon or isoflurane anaesthesia: a randomized controlled trial. BMC Anesthesiol. 2010 May 7;10:5. doi: 10.1186/1471-2253-10-5."
            }, 
            {
                "PMID": "18952398", 
                "citation": "Diemunsch P; Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation. [Conference of experts--short text. Management of postoperative nausea and vomiting. French Society of Anesthesia and Resuscitation]. Ann Fr Anesth Reanim. 2008 Oct;27(10):866-78. Epub 2008 Oct 25. French."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Measure of Systolic ejection volume", 
                "safety_issue": "Yes", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "measure": "Assess the number of days including the surgery date and the discharge date", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Assess the number of minutes between the end of surgery and postoperative room exit", 
                "safety_issue": "No"
            }, 
            {
                "description": "in mg/Kg", 
                "measure": "Assess the total dose administered of vasopressive and hypotensive agents", 
                "safety_issue": "No", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "description": "in mL/Kg/hour", 
                "measure": "Assess the volume of each product administered for hydration", 
                "safety_issue": "No", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "description": "required to maintain BIS between 40 and 60 (in mg/kg)", 
                "measure": "Assess the total dose of morphinics", 
                "safety_issue": "No", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "measure": "Assess the Aldrete score and Recovery Index", 
                "safety_issue": "No", 
                "time_frame": "5 minutes after eyes opening"
            }, 
            {
                "measure": "Assess the number of days until an oral feeding", 
                "safety_issue": "No"
            }, 
            {
                "description": "according to the NCI-CTC version 4.03", 
                "measure": "Patients with Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "45 days after surgery"
            }, 
            {
                "measure": "Assess the Score to Visual analog scale for pain", 
                "safety_issue": "No", 
                "time_frame": "At entrance and exit of post operative room and 24 hours after the end of anesthesia"
            }, 
            {
                "measure": "Measure of corrected ejection time", 
                "safety_issue": "Yes", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "measure": "Measure of heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "All along the maintenance of anesthesia, an expected average of 6 hours"
            }, 
            {
                "measure": "Assess the delay of bowel movement recovery", 
                "safety_issue": "No"
            }
        ], 
        "source": "Centre Leon Berard", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Leon Berard", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}